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Abstract: Complex problems in life science research give rise to multidisciplinary collaboration, and hence, to the need for 
heterogeneous database integration. The tumor suppressor p53 is mutated in close to 50% of human cancers, and a small 
drug-like molecule with the ability to restore native function to cancerous p53 mutants is a long-held medical goal of cancer 
treatment. The Cancer Research DataBase (CRDB) was designed in support of a project to fi nd such small molecules. As a 
cancer informatics project, the CRDB involved small molecule data, computational docking results, functional assays, and 
protein structure data. As an example of the hybrid strategy for data integration, it combined the mediation and data ware-
housing approaches. This paper uses the CRDB to illustrate the hybrid strategy as a viable approach to heterogeneous data 
integration in biomedicine, and provides a design method for those considering similar systems. More effi cient data sharing 
implies increased productivity, and, hopefully, improved chances of success in cancer research. (Code and database schemas 
are freely downloadable, http://www.igb.uci.edu/research/research.html.)
Keywords: Cancer, Data Warehousing, Heterogeneous Database Integration, Hybrid Database Integration, Mediation, p53.
Introduction
A long-held medical goal of cancer therapy is the discovery of small drug-like molecules able to rescue 
cancerous p53 mutants (Bullock and Fersht, 2001; Wang, Rastinejad, and El-Deiry, 2003; Bykov, 
Selivanova, and Kilman, 2003; Baroni et al. 2004; Brachmann, 2004). Toward this goal, different p53 
data is produced by ten collaborating research laboratories within four Schools at the University of 
California, Irvine (UCI): p53 cancer and suppressor mutations, and functional assays (in the School of 
Medicine) (Baroni et al. 2004; Dearth et al. 2006); bioinformatics and computational docking (Donald 
Bren School of Information and Computer Sciences) (Swamidass et al. 2005; Danziger et al. 2006); 
small molecule synthesis (School of Physical Sciences); and Nuclear Magnetic Resonance (NMR), 
X-ray crystallography, and other structural assays (School of Biological Sciences). This led to a need 
to develop a heterogeneous database that integrated each laboratory’s data.
Similar situations are very common in biomedical research and practice where multiple groups from 
diverse disciplines collaborate. This is especially true for complex diseases, such as cancer, where many 
interacting disciplines may be necessary for a successful attack. Each group often stores experimental 
data in a local, autonomous database. Consequently, related biomedical data is stored in multiple 
databases, which frequently have different schemas and are implemented with different technologies 
(Markowitz and Ritter, 1995). Database heterogeneities make access to information diffi cult (Sujansky, 
2001).
Thus, multidisciplinary collaboration often gives rise to the need for heterogeneous databases. A het-
erogeneous database unites various databases, which have different schemas and technologies, by 
providing a uniform database schema and querying capabilities that integrate distributed data (Sujansky, 
2001). The process of integrating data from multiple, autonomous, and heterogeneous sources is called 
heterogeneous database integration (Sujansky, 2001). Heterogeneous database integration is critical in 
biomedical discovery (Lacroix and Critchlow, 2003).
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Heterogeneous database integration is a 
challenging topic, important in several application 
domains (Karasavvas et al. 2004), and is one of the 
most important computer science problems today 
(Zhou et al. 1995). It is especially diffi cult in bio-
medicine because biological data is inherently 
complex, in that (a) most rules have exceptions; 
(b) data is richly varied, from DNA and protein 
sequences to three-dimensional images to XML to 
fl at fi les; and (c) there are complex associations 
between objects (Karasavvas et al. 2004).
This paper illustrates the hybrid database inte-
gration strategy as a viable approach to heteroge-
neous database integration in biomedicine, and 
suggests design principles for others considering 
similar projects. Here, the hybrid strategy was 
applied to a cancer informatics project involving 
p53 data from multiple laboratories. A global data-
base schema was designed that captured each 
laboratory’s data. Heterogeneous p53 data sources 
were integrated by combining the mediator and the 
data warehouse approaches. More effi cient data 
sharing implies increased productivity, and, hope-
fully, improved chances of success in cancer 
research.
p53 Background
The central tumor suppressor protein p53 helps 
prevent uncontrolled cell growth. Upstream stress 
signals, such as DNA damage, lead to the activation 
of p53, which functions as a transcription factor 
for downstream genes involved in DNA repair, cell 
cycle arrest, and programmed cell death (apopto-
sis). Thus, p53 helps prevent a cell from propagat-
ing mutations due to DNA damage. If the p53 gene 
is mutated or missing and the cell with damaged 
DNA continues to divide, cancer may result (Prives 
and Hall, 1992; Vogelstein, Lane, and Levine, 
2000). In fact, it is estimated that close to 50% of 
human cancers have p53 inactivated due to gene 
mutations (Hollstein et al. 1991; Olivier et al. 
2002). Furthermore, cancers with inactive mutant 
p53 are diffi cult to treat because they are espe-
cially resistant to radiation and chemotherapy 
(Wallace-Brodeur and Lowe, 1999; Soussi and 
Beroud, 2001).
Database Background
and Related Work
Heterogeneous database integration has been 
studied in the database research community for 
many years. However, no preferred solution or 
agreement of approach currently exists (Widom, 
1996). In this section, fi rst, the main challenges in 
heterogeneous biomedical database integration are 
described briefl y. Then, we discuss approaches that 
have been proposed for heterogeneous database 
integration, including data warehousing, media-
tion, a less common hybrid strategy, and others.
Challenges in Heterogeneous 
Biomedical Database Integration
Heterogeneous database systems are computational 
models and software implementations that provide 
a single, uniform query interface to data that are 
stored and managed in multiple, heterogeneous 
data sources (Sujansky, 2001). The goal of such 
systems is to provide database transparency to 
users as if the data were not distributed and all of 
the data sources were of the same type. Despite 
standardization efforts, it is believed in the research 
community that database heterogeneity will (and 
should) remain (because to prohibit heterogeneity 
would prohibit innovation). This is especially the 
case in the biomedical domain (Sujansky, 2001). 
Here, we summarize some of the main challenges 
involved in heterogeneous biomedical database 
integration.
1) Query Models: The core challenge of hetero-
geneous database integration, in biomedical and 
other domains, is that different data sources have 
different query models. A query model (Sujansky 
and Altman, 1994; Sujansky, 2001) is the model 
of data storage and information retrieval that a user 
of the database must know in order to retrieve data 
from it. A query model consists of the data model, 
database schema, query language, and data format. 
For example, biomedical data is variously stored 
in fl at fi les, XML fi les, binary fi les, spreadsheets, 
and in relational, object-relational, and object-
oriented databases (Chung and Wooley, 2003).
2) Autonomous Data Sources: Usually, bio-
medical data sources are autonomous (Chung and 
Wooley, 2003). This means that developers of the 
heterogeneous database do not have control over 
the data sources to be integrated. Each data source 
is free to modify its data and schema, and to restrict 
access to it (Karasavvas et al. 2004).
3) Data Diversity: Often, life science data to be 
integrated is very diverse, encompassing several 
research fi elds (Chung and Wooley, 2003; Hernandez 
and Kambhampati, 2004). This data ranges from 
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fl at fi les and literature publications, DNA and 
protein sequences, gene expression data, protein-
protein interactions, molecular structures, and 
biomedical images to microarray chips, gels, light 
and electronic microscopy, NMR, and mass spec-
trometry. Furthermore, this data is often incom-
plete, inconsistent, and frequently updated. This 
diversity presents a major challenge in integrating 
biological data (Chung and Wooley, 2003).
4) Representational Heterogeneity: Similar data 
are often represented differently in different data 
sources. This representational heterogeneity con-
sists of structural, naming, semantic, and content 
differences (Sujansky, 2001). Structural differences 
refer to schema differences. Naming (syntactic) 
differences occur when semantically equivalent 
objects (table and fi elds as well as data in fi elds) 
are named differently in different data sources. 
Semantic differences occur when names of objects 
in different data sources are similar or the same, 
but their meanings differ. Semantic ontologies may 
differ (McEntire et al. 2000). Content differences 
refer to differences in data between the data 
sources. The data may be implicit, derivable, or 
missing.
5) Technical Heterogeneity: These challenges 
occur due to differences in hardware platforms, 
operating systems, access protocols, transport 
formats, and programming languages between the 
data sources (Karasavvas et al. 2004).
Data Warehousing
In data warehousing (Widom, 1995), data from 
each source is extracted, merged, and stored in a 
centralized repository (warehouse). The warehouse 
is a database with a global schema that combines 
the schemas of the sources. Queries on the system 
are evaluated at the warehouse without accessing 
the original sources. Client updates to the ware-
house are usually not allowed since they are not 
propagated to the original sources and would make 
the warehouse inconsistent with the sources. 
Instead, the warehouse is updated from the data in 
the sources. There are multiple policies for updat-
ing the warehouse from the sources (Garcia-
Molina, Ullman, and Widom, 2000).
Database integration based on data warehousing 
relies less on the network, and allows for improved 
query performance and optimization since queries 
are processed locally in the warehouse. Further-
more, since a local copy of the data is kept in a 
separate database from the data sources, data 
warehousing allows for data to be cleansed, anno-
tated, and summarized (Widom, 1995; Hernandez 
and Kambhampati, 2004). The drawback of this 
approach is data duplication. This increases the 
cost of maintenance, the potential for data incon-
sistency, and the probability of outdated query 
results (Sujansky, 2001; Hernandez and Kambham-
pati, 2004). In general, data warehousing is suited 
for applications with predictable queries, applica-
tions requiring high query performance, and appli-
cations needing private copies of the data. 
Biomedical database integration systems that use 
the data warehousing approach include IGD (Rit-
ter et al. 1994), GIMS (Cornell et al. 2001), GUS 
(Davidson et al. 2001), DoTS (http://www.allgenes.
org/), Qu et al. (2002), and Tsou et al. (2006).
Mediation
In mediation (Weiderhold, 1992; Domenig and 
Dittrich, 1999), a module called a “mediator” 
accepts a query from the client, determines the 
sources needed to answer the query, and decom-
poses the query into subqueries for each required 
source. The subqueries are translated to the source-
specific query language via modules called 
“wrappers.” The results from the sources are trans-
lated back into the common query language by the 
wrappers. Finally, the mediator obtains results from 
the wrappers, combines them, and returns the fi nal 
answer to the client. Mediation is the most common 
approach to data integration in biomedi-cine 
(Karasavvas et al. 2004).
Mediation can be query-centric (also known as 
global-as-view) or source-centric (also known as 
local-as-view) (Ullman, 1997; Li, 2001; Li, 2003; 
Hernandez and Kambhampati, 2004). In query-
centric mediaton, users pose queries on the global 
views exported by the mediator. The mediator uses 
global views to expand user queries to queries on 
source data. In source-centric mediation, global 
predicates are used to construct source views and 
to pose user queries. The mediator uses source 
views to answer user queries. Ullman (1997) pres-
ents a detailed comparison of these two approaches 
to mediation.
The main advantage of mediation is that it 
reduces the maintenance required when data 
sources are modifi ed or when new ones emerge. 
However, in contrast to data warehousing, media-
tion relies heavily upon the network, and can 
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experience query performance degradation due to 
high network traffi c, slow response, and unavail-
ability of data sources (Sujansky, 2001; Hernandez 
and Kambhampati, 2004). Furthermore, the 
mediation approach is much more difficult to 
implement, and it is not feasible for data sources 
that do not support ad hoc queries. In general, 
mediation is appropriate for data that changes 
rapidly, for data with unpredictable queries, for 
sources that are reliable, and for queries on large 
amounts of data from many sources. Biomedical 
database integration systems that use the mediation 
approach include BioKleisli (Davidson et al. 
1997), OPM Tools (Markovitz et al. 1999), TAM-
BIS (Goble et al. 2001), K2 (Davidson et al. 2001), 
DiscoveryLink (Haas et al. 2001) and P/FDM 
(Kemp, Angelopoulos, and Gray, 2002).
Hybrid Strategy
Voisard and Jürgens (1999) propose a hybrid strat-
egy to data integration that combines data ware-
housing and mediation approaches. In the hybrid 
strategy, part of the data is queried on demand as 
in the mediation approach, but other data is 
extracted, fi ltered, and stored in the warehouse 
(Widom, 1996; Voisard and Jürgens, 1999). Ashish 
(2000) proposes a hybrid strategy as a way to 
improve the performance of a mediation approach 
by selectively importing data into the warehouse. 
In both (Voisard and Jürgens, 1999; Ashish, 2000), 
the warehouse is treated like a regular data source 
in a mediation approach. The hybrid strategy used 
in this paper is similar to the one implemented in 
Squirrel (Hull and Zhou, 1996). Squirrel imple-
ments a special mediator called a “Squirrel integra-
tion mediator” that queries part of the data on 
demand and stores other data in its materialized 
data storage. The disadvantage of Squirrel is the 
assumption that the underlying sources are 
databases.
Many large-scale database integration systems 
of the future will require both mediation and data 
warehousing (Widom, 1996; Voisard and Jürgens, 
1999). While the best approach to data integration 
varies with the application, it is likely to be a hybrid 
strategy based on the combination of different 
approaches (Eckman, 2003). Such a hybrid strat-
egy is less frequently discussed in the database 
literature compared to each approach alone, and 
this is even more true in biomedical database 
integration.
Other Approaches
Federated database systems (Sheth and Larson, 
1990; Garcia-Molina et al. 2000) integrate data-
bases by implementing one-to-one connections 
between all databases that need to communicate 
with each other. Software components are written 
to translate queries between the databases. The 
disadvantage of this approach is that translation 
components need to be written for every pair of 
communicating databases. However, when limited 
communication between the databases is required, 
this approach may be the easiest to implement 
(Garcia-Molina et al. 2000).
Karasavvas et al. (2004) argue that agent tech-
nology is well suited for heterogeneous biomedical 
database integration as there are many similarities 
between multi-agent systems (MASs) and hetero-
geneous database systems based on the mediation 
approach. In this approach, Agent Communicating 
Languages (ACLs) act as common query lan-
guages, and ACLs and ontologies deal with techni-
cal and representational heterogeneities, 
respectively. Resource agents (RAs) act as wrap-
pers in the mediation approach. In addition, the use 
of agent standards helps standardize database inte-
gration.
Philippi and Köhler (2004) propose an XML-
based, ontology-driven approach based on data 
warehousing. First, the data sources to be integrated 
are converted from their native format into XML 
format. Then, these XML documents are inserted 
into a data warehouse, and are semantically defi ned 
against one or more ontologies (McEntire et al. 
2000), which serve as semantic references. In addi-
tion, semantic defi nitions of data sources need to 
be generated. The authors’ motivation for using 
XML is that it is becoming a standard for data 
exchange in the life sciences (Achard, Vaysseix, 
and Barillot, 2001). To query the data warehouse, 
semantic query generation components are created 
that use the ontologies and semantic defi nitions of 
data sources. In this approach, syntactic and sche-
matic differences between the data sources are 
resolved by using XML, and semantic differences 
are resolved through ontologies and semantic data 
source defi nitions. The advantages of this approach 
are that no integrated schema needs to be developed 
to provide integrated access to heterogeneous data 
sources, and changes in data sources do not affect 
the system. The disadvantages are that an XML 
database is needed for the data warehouse, an XML 
converter needs to be developed for each data 
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source, and the quality of query results depends on 
the quality of the ontologies.
Design Considerations
The design goal of the Cancer Research DataBase 
(CRDB) was to integrate data produced by col-
laborating research laboratories at the University 
of California, Irvine (UCI). The CRDB should 
allow researchers to share data, provide their 
results, and communicate effi ciently, across labo-
ratories in a common and convenient framework 
accessible through the Internet. However, the 
CRDB should not simply reproduce the sources’ 
data. The CRDB should store only the results that 
at least one laboratory feels would be interesting 
to other laboratories. In addition, the CRDB should 
not store all of the data features. It should store 
only the most important attributes of the data.
Data Description
The CRDB integrated data that relates to experi-
ments performed on small molecules with the goal 
of fi nding small molecules that restore function to 
p53 mutants and can be developed into new anti-
cancer drugs. Computational docking is performed 
on a library of compounds to identify small mole-
cules that have potential of restoring native function 
to p53 mutants. Each docking experiment is done 
on a specifi c docking target, here a p53 mutant. A dock-
ing target has multiple binding sites to which small 
molecules may bind. A molecule may have multiple 
conformations. The conformation of a molecule is 
its three-dimensional shape defi ned by angles of 
rotation about its bonds, as specifi ed in a mol2 fi le. 
Docking uses computer algorithms to model how 
a molecule binds to a binding site of the target. The 
result of a docking experiment is a score that mea-
sures the ability of the molecule to bind the target’s 
binding site. Molecules with the best scores are 
synthesized. Finally, the synthesized molecules are 
assayed on the p53 mutants to determine what effect 
they have on the mutants.
Design Method
Previously, a database containing p53 cancer and 
suppressor mutations had been developed 
(“Mutants” data). We wanted to expand the data-
base to contain the rest of the data (“Molecular” 
data). It was determined that it would be 
impractical simply to import the “Molecular” data 
into the database as in the data warehousing 
approach, and that the mediation approach was 
needed for a subset of the “Molecular” data. 
Therefore, we decided to implement a hybrid 
strategy to data integration by combining data 
warehousing and mediation approaches. Here, we 
describe the principles behind the design of the 
CRDB.
There are many ways to create a hybrid database 
architecture. It is a major design decision to deter-
mine what part of the data to import into the ware-
house and what part to query on demand. In 
determining which approach to implement for a 
given data source, the designer needs to consider 
the characteristics of the data and the data source. 
Voisard and Jürgens (1999) discuss detailed general 
principles for the design of a hybrid strategy. 
Table 1 summarizes those principles used here.
In deciding which data integration approach to 
implement for each data source, it is possible to 
apply the principles in Table 1 in a qualitative man-
ner by considering the requirements of the applica-
tion and characteristics of the data source. However, 
as the number and complexity of data sources 
increase, qualitative design methods may become 
imprecise and inadequate. Instead, a more rigorous, 
quantitative method was applied in the design of 
the CRDB, which is shown in Table 2.
First, data sources were classifi ed based on their 
characteristics as shown in Table 2A. Then, using 
the principles in Table 1, each characteristic was 
converted to the data integration approach that 
best implements that characteristic as shown in 
Table 2B. For example, data that changes periodi-
cally is best stored in a data warehouse while data 
that changes often is best accessed through medi-
ation. Third, each approach was assigned a numer-
ical value with warehouse = 1 and mediation = 0, 
and a design score was calculated for each data 
source by summing across the characteristics as 
shown in Table 2C. If a given data source had a 
score of 5 in Table 2C, it would be an ideal candi-
date for data warehousing; while if it had a score 
of 0, it would be ideal for mediation. In practice, 
most data sources are unlikely to be exactly ideal 
for either mediation or data warehousing; more 
likely, they would have some traits that favored 
one approach and other traits that favored the other 
approach. Thus, a median score of 2.5 was used to 
decide which approach to use for each data source. 
A data source with a score above the median was 
implemented with data warehousing, while one 
with a score below the median used mediation.
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In theory, one wouldlike to use all of the 
principles in an optimal way. In practice, however, 
there are trade offs that need to be made between 
the principles. Mediation approach was chosen for 
computational docking and small molecule data 
even though query processing time may not be the 
best, because the size of the data and the frequency 
of data updates clearly favored this approach. On 
the other hand, implementing the data warehousing 
approach for computational docking and small 
molecule data would have improved query perfor-
mance, but would have required frequent ware-
house updates in order to maintain consistency of 
the warehouse and the high quality of query 
results.
System Description
The CRDB was developed using Microsoft SQL 
Server 2000. The CRDB ran on IBM PC (Pentium) 
with a Microsoft Windows 2003 Server operating 
system. A global database schema was designed 
that captured all of the data. Computational dock-
ing and small molecules were integrated via con-
nections to the research laboratories’ databases. 
Functional and structural assays were integrated 
by importing them into the CRDB. Connectivity 
between the CRDB and the web interface was 
provided by a ColdFusion application engine run-
ning on the server.
Global Database Schema
A global database schema was designed that was 
able to store all of the data. The global database 
schema is shown in Fig. 1. Each molecule (“Mol-
ecules” table) may have more than one conforma-
tion (“Conformations” table) and it may come from 
more than one source (“Sources” table). There are 
two types of experiments (“Experiments” table) 
that are done on molecules: computational docking 
and biological assays. The results (“Dock-
ingResults” and “AssayResults” tables) of these 
experiments were captured in the database. Each 
type of experiment is done on a particular p53 
mutant (“Mutants” table) and has a score (“Scores” 
table) associated with it.
The global schema design proved to be a dif-
fi cult task. We had diffi culty determining exactly 
what data needed to be integrated and how it ought 
to be stored. As a result, several design iterations 
were required. From the data, we identifi ed two 
main results: docking and assay results. Each result 
was associated with different conditions: experi-
ments, mutants and molecules. Thus, the schema 
followed a design pattern of “DockingResults” 
and “AssayResults” tables related to “Experi-
ments,” “Mutants” and “Molecules” tables. This 
made the schema fl exible to changes. If a new 
laboratory were to emerge that performed other 
experiments on molecules and mutants, a new 
Table1. CRDB design principles.
• Changes to data
Mediation approach should be used for data that changes often. Data warehousing approach should be used 
for data that changes periodically.
• Size of the data
Mediation approach should be used for larger data. Data warehousing approach should be used for smaller 
data.
• Availability of sources
Mediation approach should be used for sources that are always available. Data warehousing approach should 
be used for sources that are often unavailable.
• Required query processing time
Mediation approach should be used for data with fl exible timing constraints. Data warehousing approach 
should be used for data with stringent timing constraints.
• Predictability of queries
Predictable queries on data that does not change often should be written in advance with the results stored in 
the warehouse. In addition, knowledge of the queries to be performed on the system should be taken into 
consideration during global schema design.
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“Results” table could be created with relationships 
to “Experiments,” “Mutants” and “Molecules” 
tables. Alternatively, if a new condition were to 
emerge, a new “Condition” table could be created 
with relationships to “DockingResults” and 
“AssayResults” tables.
Hybrid Database Integration
The CRDB system architecture and the hybrid 
strategy to data integration are shown in Fig. 2. 
The CRDB included both a mediator and a data 
warehouse. The warehouse part of the CRDB 
consisted of two sub-warehouses (data marts) cor-
responding to the “Mutants” data and the “Molec-
ular” data. Computational docking was integrated 
via a connection from the CRDB to the laborato-
ry’s PostgreSQL database. In integrating compu-
tational docking data, we had two options: (1) 
import the data into the CRDB, or (2) connect from 
the CRDB to the laboratory’s database storing the 
computational docking data. Since the computa-
tional docking data was a large, frequently updated 
data set with millions of docking runs, we decided 
on the second option. The connection was imple-
mented via the “Linked Servers” feature of Micro-
soft SQL Server. This was a convenient way of 
connecting two database servers, and was chosen 
for its availability and convenience. The ODBC 
driver for PostgreSQL acted as a wrapper that 
translated a query written in SQL Server into a 
query that PostgreSQL understands.
Functional assays were integrated by importing 
them intothe CRDB. We fi rst imported functional 
assay data into a temporary table in the SQL 
Server database management system (DBMS) 
using the Data Transformation Services (DTS) 
feature of SQL Server. Because functional assay 
data was stored in Microsoft Excel spreadsheets, 
we needed to implement a wrapper that translated 
it from the spreadsheet format into the format and 
data model of CRDB. The wrapper was imple-
mented as a data transformation stored procedure 
in SQL Server. Once translated, we again used 
DTS to insert functional assays into the CRDB. 
This approach to importing the functional assay 
Table 2. CRDB design method. A. Data sources were classifi ed based on their characteristics. B. Each 
characteristic was converted to the data integration approach that best implements it. C. Each approach was 
assigned a numerical value with warehouse = 1 and mediation = 0, and a design score was calculated for each 
data source by summing across the characteristics.
A
Data Source Data 
Changes
Data 
Size
Source 
Availability
Timing 
Constraints
Query 
Predictability
Docking often large sometimes fl exible low
Small Molecules often large sometimes fl exible high
Functional Assays periodically small sometimes fl exible high
Structural Assays periodically small sometimes fl exible low
B
Data Source Data 
Changes
Data 
Size
Source 
Availability
Timing 
Constraints
Query 
Predictability
Docking mediation mediation warehouse mediation mediation
Small Molecules mediation mediation warehouse mediation warehouse
Functional Assays warehouse warehouse warehouse mediation warehouse
Structural Assays warehouse warehouse warehouse mediation mediation
C
Data Source Data 
Changes
Data 
Size
Source 
Availability
Timing 
Constraints
Query 
Predictability
Design 
Score
Docking 0 0 1 0 0 1
Small Molecules 0 0 1 0 1 2
Functional Assays 1 1 1 0 1 4
Structural Assays 1 1 1 0 0 3
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data into the warehouse was chosen because of its 
availability and convenience within the SQL 
Server DBMS.
Computational docking and small molecule data 
were queried on demand by accessing the labora-
tories’ databases without importing them into the 
CRDB. Thus, for computational docking and small 
molecule data, the CRDB acted as a mediator. On 
the other hand, functional and structural assays 
were imported into the CRDB. In these cases, the 
CRDB acted as a data warehouse. Therefore, the 
overall strategy for heterogeneous database inte-
gration was hybrid.
The integration of small molecule and structural 
assay data is planned in the future. In integrating 
small molecule data, we will use the same approach 
as in computational docking. We will connect from 
the CRDB to the laboratory’s MySQL database via 
the “Linked Servers” feature. Similar to functional 
assays, structural assays will be integrated by fi rst 
translating them from the native formats into the 
warehouse format, and then importing them into 
the CRDB via DTS.
Results and Discussion
This paper presented the Cancer Research Data-
Base (CRDB) as an example of the hybrid strategy 
for heterogeneous biomedical database integration. 
The system architecture combined the data ware-
house and the mediator within one entity. The 
CRDB was designed for p53 researchers in order 
to provide inter-laboratory communication for their 
efforts to discover small molecules that can restore 
native function to p53 cancer mutants. The 
researchers were able to query p53 mutants, func-
tional assays, and computational docking data 
individually and in combination.
A researcher interactively specifi ed a query 
through the selection of graphical user interface 
components. Depending on the query, the appropri-
ate stored procedure was executed. For example, 
Figure 1. CRDB global database schema. The schema follows a design pattern with “Condition” tables (Molecules, Mutants, Experiments) 
related to “Results” tables (DockingResults and AssayResults). PK denotes a primary key.
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suppose a p53 researcher wishes to know with 
which p53 DNAbinding sites does the p53 mutant 
C141Y show activity, and which suppressor muta-
tions (Baroni et al. 2004) rescue C141Y in the 
functional assay. The researcher selects the mutant 
name from the functional assay data drop down 
list, the stored procedure is executed that queries 
the functional data in the warehouse part of the 
CRDB, and the results are displayed.
For another example, suppose a p53 researcher 
wishes to know the results of docking studies done 
on p53 mutant G245S. In this case, after the 
researcher selects the mutant name from the dock-
ing data drop down list, the CRDB acts as a 
mediator by querying the docking laboratory’s 
PostgreSQL database. First, a query written as a 
SQL Server stored procedure is translated by the 
ODBC driver for PostgreSQL into a query that 
PostgreSQL understands. Then, the ODBC driver 
returns results from PostgreSQL to the CRDB. 
Finally, the results are displayed.
Developing a database that integrates data from 
different sources is a diffi cult task. Requirements 
analysis is essential. Multiple design iterations are 
inevitable. It is necessary to understand what data 
needs to be stored and its characteristics, what data 
is produced by each source, and what queries are 
to be performed on the database. It is also impor-
tant to understand the characteristics of the data 
sources, such as how the data is stored, accessed, 
and updated locally. All of these factors need to 
be taken into account during the design of the 
Figure 2. System architecture and the hybrid strategy to data integration. Docking and small molecule data use the mediation approach, 
while the functional and structural assay data use the data warehousing approach. The CRDB is both a mediator and a data warehouse. 
“Mutants” and “Molecular” are data marts of the warehouse. The ODBC drivers are wrappers in the mediation approach. Dashed lines 
indicate integration planned in the future.
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global database schema and the overall system 
architecture.
In heterogeneous database integration, global 
schema design is the most critical, challenging, 
and time consuming phase. The design diffi culty 
is compounded in that some sources do not have 
a database structure, and so store data in various 
software systems such as Microsoft Excel and fl at 
fi les. This makes data integration more diffi cult 
because there is no standard method of connecting 
to the data.
When deciding which approach to implement 
for given data, the designer needs to consider the 
requirements of the application, the various param-
eters associated with the data and the data source 
(Voisard and Jürgens, 1999), and the various 
approaches to data integration including their 
strengths and weaknesses. For data that requires 
high query performance, or needs to be cleansed, 
annotated, or summarized, data warehousing is 
usually the best approach. Otherwise, mediation is 
an excellent choice since it may not require the 
development of a full global database schema.
Other important issues in heterogeneous data-
base integration include data standards, ontologies, 
data annotation, and metadata. Data standards (also 
known as data exchange formats) may be used to 
help resolve schema and syntactic differences and 
to avoid developing multiple data transformation 
tools (Markowitz et al. 2003). In developing the 
CRDB, we did not impose a data standard because 
the sources had relatively small areas of overlap-
ping content. However, in the future, as we inte-
grate more data and more laboratories join the 
effort, a data standard may be suitable at least for 
the subset of the source data.
Ontologies are used to help resolve semantic 
differences and to facilitate querying across mul-
tiple data sources from diverse domains (McEntire 
et al. 2000; Chung and Wooley, 2003; Philippi and 
Köhler, 2004). In the current implementation, we 
did not fi nd a great need for an ontology because 
the cooperating laboratories were largely consistent 
in their semantic usage. However, as the effort 
expands, an ontology may become necessary. Data 
annotation involves inferring additional informa-
tion or knowledge about the data (Chung and 
Wooley, 2003; Hoebeke et al. 2005). In developing 
the CRDB, each laboratory provided all of the 
needed information about its data. Metadata, data 
describing data, facilitates more effective querying 
and interpretation of results. It is useful for the 
heterogeneous database to provide metadata on 
how the integrated data was generated and derived 
(Chung and Wooley, 2003).
Given the diversity of life science data, and the 
heterogeneous data sources in which this data is 
stored, there is no single “best” approach to het-
erogeneous database integration in biomedicine. 
The hybrid strategy is an attractive option. The 
goal of the hybrid strategy is to incorporate the 
strengths of multiple approaches while avoiding 
their weaknesses.
Conclusions
This paper illustrated the hybrid strategy as a 
viable approach to heterogeneous database inte-
gration, one of the most important computer sci-
ence problems today (Zhou et al. 1995), in a 
cancer informatics project involving p53. More 
examples are required to assess fully the advan-
tages and disadvantages of hybrid database sys-
tems. Nonetheless, the hybrid strategy can provide 
a useful alternative system architecture for the 
designer facing the diffi cult choices that accom-
pany heterogeneous database integration in 
biomedicine.
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